IT Manager/Senior IT Manager
Frontier Medicines
IT Manager/Senior IT Manager
Frontier Medicines
Develops precision oncology drugs using chemoproteomics
Frontier Medicines · Boston, United States · Contract · Posted 2026-11-12
Workplace: on_site
Department: IT
What’s in it for you?
Frontier Medicines is seeking an IT Manager/Sr. IT Manager to lead our core infrastructure, security, and platform administration as part of a small IT team. You will work hands-on with the systems our scientists and business teams rely on every day, from the data center and network to identity, cloud, and device management.
This is a 3-month contract-to-hire role, with the opportunity to convert to a full-time position if it is a strong fit on both sides. It is an individual contributor role with no direct reports. You will lead your areas from day-to-day administration through planning and vendor relationships, working closely with the rest of the IT team. The ideal candidate is comfortable in a lean, fast-moving biotech environment, works independently, and is ready to take on whatever the environment needs. This role is on site in our Boston office in Seaport.
What will you be doing?
Traits we believe make a strong candidate:
At Frontier, we strive to build a diverse and equitable workplace. The salary range for this role is $118,000 - $185,000 annually. Compensation for the role will depend on a number of factors, including hours worked, candidates' qualifications, skills, competencies and experience. Frontier offers a competitive total rewards package which includes healthcare coverage, 401k and a broad range of other benefits.
This compensation and benefits information is based on Frontier's knowledge as of the date of publication, and may be modified in the future.
Powered by Workable
Develops precision oncology drugs using chemoproteomics
Frontier Medicines develops precision medicines for genetically defined patient populations, mainly in oncology and other hard-to-treat diseases. It uses chemoproteomics, covalent drug discovery, and machine learning to identify small molecules against difficult targets and advances candidates through clinical development toward commercialization. Its lead program FMC-376 targets KRAS G12C in both active and inactive states, and it has built the AutoTAC platform for targeted protein degradation to expand potential drug modalities. The company differentiates itself by combining genetics-driven target selection with advanced proteomics and chemistry within a platform approach that supports partnerships and licensing with larger pharma to bring therapies to patients.
Explore more opportunities at Frontier Medicines